MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Copaxone

Company: Teva Pharmaceutical
Approval Status: Approved January 1997
Treatment for: Relapsing-remitting multiple sclerosis
Areas: Neurology & Nervous System

| General Information | Clinical Results | Side Effects | Additional Information |


General Information

Copaxone has been approved for the treatment of relapsing-remitting multiple sclerosis.


Clinical Results

In a two-year multicenter, randomized, double blind, placebo-controlled trial of 251 patients, copaxone (glatiramer acetate for injection) was shown to reduce relapses by an average of 29 percent when compared with placebo.


Side Effects

The most common side effects associated with the use of copaxone included injection site reactions, flushing, chest pain, weakness, infection, pain, nausea, joint pain, anxiety and muscle stiffness.


Additional Information

Multiple sclerosis is a chronic, often progressive disease of the central nervous system (brain, spinal cord and optic nerves), which affects 300,000 people in the United States (approximately 10,000 people are diagnosed each year). The disease most often appears in people between the ages of 20 and 40. Approximately 73 percent of people with multiple sclerosis are female.




< back to top

Copaxone Drug Information

The Copaxone drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.